Loading...
XNASFGEN
Market cap65mUSD
Jan 08, Last price  
0.65USD
1D
4.23%
1Q
93.12%
Jan 2017
-96.96%
IPO
-97.27%
Name

FibroGen Inc

Chart & Performance

D1W1MN
XNAS:FGEN chart
P/E
—
P/S
0.44
EPS
—
Div Yield, %
3.44%
Shrs. gr., 5y
2.97%
Rev. gr., 5y
-7.05%
Revenues
148m
+4.99%
65,933,000102,170,000137,601,000180,828,000179,577,000125,668,000212,958,000256,577,000176,319,000235,309,000140,734,000147,752,000
Net income
-284m
L-3.72%
-32,571,000-14,943,000-59,504,000-85,779,000-61,680,000-126,203,000-86,420,000-76,970,000-189,291,000-291,030,000-295,227,000-284,232,000
CFO
-315m
L+115.87%
-5,605,00025,918,00022,414,000-18,571,0007,108,000-66,513,000-76,144,000-78,705,00081,602,000-82,232,000-145,933,000-315,021,000
Earnings
Feb 24, 2025

Profile

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. It is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Phase III trial for the treatment of Duchenne muscular dystrophy. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.
URL
https://www.fibrogen.com/
IPO date
Nov 14, 2014
Employees
592
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
147,752
4.99%
140,734
-40.19%
Cost of revenue
301,709
317,071
Unusual Expense (Income)
NOPBT
(153,957)
(176,337)
NOPBT Margin
Operating Taxes
3
358
Tax Rate
NOPAT
(153,960)
(176,695)
Net income
(284,232)
-3.72%
(295,227)
1.44%
Dividends
(2,255)
Dividend yield
2.61%
Proceeds from repurchase of equity
48,407
(983)
BB yield
-56.13%
0.07%
Debt
Debt current
14,077
10,292
Long-term debt
236,952
169,478
Deferred revenue
157,555
185,722
Other long-term liabilities
54,167
72,690
Net debt
10,153
(251,647)
Cash flow
Cash from operating activities
(315,021)
(145,933)
CAPEX
(2,519)
(38,741)
Cash from investing activities
153,657
89,116
Cash from financing activities
122,749
46,776
FCF
(134,834)
(157,043)
Balance
Cash
235,586
422,008
Long term investments
5,290
9,409
Excess cash
233,488
424,380
Stockholders' equity
(1,805,840)
(1,542,499)
Invested Capital
2,025,778
1,881,625
ROIC
ROCE
EV
Common stock shares outstanding
97,303
93,582
Price
0.89
-94.47%
16.02
13.62%
Market cap
86,240
-94.25%
1,499,184
15.13%
EV
138,360
1,267,504
EBITDA
(144,027)
(165,733)
EV/EBITDA
Interest
15,532
1,440
Interest/NOPBT